Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.41 |
| ▸ | IL5 | P05113 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 9/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17532781 | 0.85 | CYP2A6 (0.41) | CYP2A6CYP1A2UHRF1IL5WNT3A | |
| SCHEMBL17532792 | 0.85 | CYP2A6 (0.41) | CYP2A6CYP1A2UHRF1IL5WNT3A | |
| SCHEMBL18266952 | 0.83 | CYP2A6 (0.50) | CYP2A6CYP1A2UHRF1WNT3APDE3B | |
| SCHEMBL19044339 | 0.80 | CYP2A6 (0.47) | CYP2A6UHRF1WNT3APDE3BPDE3A | |
| SCHEMBL19497082 | 0.80 | CYP2A6 (0.44) | CYP2A6CYP1A2UHRF1IL5WNT3A | |
| SCHEMBL14908371 | 0.80 | ROCK1 (0.47) | CYP2A6CYP1A2UHRF1IL5 | |
| SCHEMBL17051661 | 0.80 | CYP1A2 (0.56) | CYP2A6CYP1A2UHRF1IL5CCR1 | |
| SCHEMBL13455997 | 0.77 | CYP2A6 (0.44) | CYP2A6PDE3BPDE3A | |
| SCHEMBL17532791 | 0.76 | MAPK10 (0.45) | CYP2A6CYP1A2IL5WNT3A | |
| SCHEMBL21133778 | 0.74 | CYP2A6 (0.54) | CYP2A6CYP1A2UHRF1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2021254493-A1 | CYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
| US-20170312277-A1 | Compounds for Treatment of Fibrosis Diseases | CUREGENIX, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-2861590-B1 | COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF | CUREGENIX INC (CN) | 2017-10-25 | — | — | EP | disclosed |
| US-9744169-B2 | Compounds for treatment of fibrosis diseases | CUREGENIX, INC. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9713612-B2 | Compounds for treatment of cancer | CUREGENIX, INC. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-20170073344-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | CUREGENIX, INC. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-9556144-B2 | Compound as WNT signaling inhibitor, composition, and use thereof | CUREGENIX, INC. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160351817-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-12-01 | — | — | US | disclosed |
| US-20160000779-A1 | Compounds for Treatment of Fibrosis Diseases | CUREGENIX, INC. (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160000780-A1 | Compounds for Treatment of Cancer | CUREGENIX, INC. (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20150119387-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | CUREGENIX INC. (CN) | 2015-04-30 | — | — | US | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000779-A1 | Compounds for Treatment of Fibrosis Diseases | WNT1, WNT3A, WNT3 | CYP2A6 2832/4885CYP1A2 2556/4885UHRF1 2121/4885 |
| US-20170073344-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | WNT1, WNT3A, SFRP1 | CYP2A6 2155/4885CYP1A2 2257/4885UHRF1 1442/4885 |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | CYP2A6 1807/4885CYP1A2 3124/4885UHRF1 3120/4885 |
| US-20170312277-A1 | Compounds for Treatment of Fibrosis Diseases | WNT1, SFRP1, WNT3 | CYP2A6 3064/4885CYP1A2 2948/4885UHRF1 2069/4885 |
| US-20150119387-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | WNT1, WNT3A, SFRP1 | CYP2A6 2280/4885CYP1A2 2408/4885UHRF1 1435/4885 |
| US-20160000780-A1 | Compounds for Treatment of Cancer | WNT1, CTNNB1, WNT3 | CYP2A6 3334/4885CYP1A2 3506/4885UHRF1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.